🇺🇸 FDA

Company profile · Sponsor

Daiichi

Daiichi Sankyo Europe GmbH

ECC3BD2 · EMA pharma München, DE
Pipeline
24
Drugs
0
Patents
0

Quick answer

Daiichi (ECC3BD2) is a pharma company. headquartered in München, DE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker ECC3BD2
Exchange EMA
Company type pharma
Headquarters München, DE

Pipeline (24)

Search pipeline →

  1. CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB

    Daiichi

    Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  2. CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN

    Daiichi

    Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  3. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Docetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DS-8201a

    Daiichi

    HER2-expressing endometrial cancer (IHC 3+/2+)

    phase 3 small molecule active

    1 trial

  4. Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ribozar 1 g Pulver zur Herstellung einer Infusionslösung, Datopotamab deruxtecan, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi

    Locally Advanced or Metastatic Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  5. DS-8201a

    Daiichi

    Advanced (unresectable or metastatic) human epidermal growth receptor 2 (HER2)-expressing/HER2-mutated solid tumors

    phase 3 small molecule active

    1 trial

  6. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion.

    Daiichi

    Metastatic breast cancer

    phase 3 small molecule active

    1 trial

  7. DS-8201a, Kadcyla 100 mg powder for concentrate for solution for infusion., Kadcyla 160 mg powder for concentrate for solution for infusion.

    Daiichi

    High-Risk HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  8. Datopotamab deruxtecan, DOCETAXEL

    Daiichi

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  9. Daunoblastin 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung, Matching placebo tablets without active substance, Idarubicin Ebewe 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Quizartinib, Citarabina Hikma 100mg/5mL Soluzione Iniettabile, Quizartinib

    Daiichi

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  10. Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  11. Ifinatamab deruxtecan, IRINOTECAN HYDROCHLORIDE, DOCETAXEL, PACLITAXEL

    Daiichi

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule active

    1 trial

  12. KEYTRUDA 25 mg/mL concentrate for solution for infusion, Datopotamab deruxtecan, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Daiichi

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. PACLITAXEL, Cyramza 10 mg/ml concentrate for solution for infusion, DS-8201a, Cyramza 10 mg/ml concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion

    Daiichi

    Metastatic Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial

  14. PACLITAXEL, Raludotatug Deruxtecan, TOPOTECAN, DOXORUBICIN HYDROCHLORIDE, LIPOSOMAL

    Daiichi

    Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer

    phase 3 small molecule active

    1 trial

  15. TOPOTECAN, TOPOTECAN, Ifinatamab deruxtecan

    Daiichi

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

  16. VEGZELMA 25 mg/mL concentrate for solution for infusion, DS-8201a

    Daiichi

    Ovarian Cancer

    phase 3 small molecule active

    1 trial

  17. CARBOPLATIN, ATEZOLIZUMAB, ETOPOSIDE, Ifinatamab deruxtecan

    Daiichi

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  18. DS-3939a

    Daiichi

    Metastatic Solid Tumor, Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  19. DS-8201a

    Daiichi

    Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer

    phase 2 small molecule active

    1 trial

  20. Datopotamab deruxtecan

    Daiichi

    Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  21. EPCORITAMAB, RITUXIMAB

    Daiichi

    Hematological Malignancies

    phase 2 small molecule active

    1 trial

  22. Ifinatamab deruxtecan

    Daiichi

    Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  23. Ifinatamab deruxtecan

    Daiichi

    Recurrent or Metastatic Solid Tumors (endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma)

    phase 2 small molecule active

    1 trial

  24. Patritumab deruxtecan

    Daiichi

    Metastatic or Locally Advanced EGFR mutated Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is Daiichi?

Daiichi (ECC3BD2) is a pharma company. headquartered in München, DE. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Daiichi sponsor?

We track 24 ClinicalTrials.gov-linked programs for Daiichi, including CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Daiichi company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.